- Report
- December 2018
- 16 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- December 2018
- 14 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- May 2021
- 45 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- March 2020
- 121 Pages
Global
From €10612EUR$10,995USD£9,103GBP
- Report
- February 2024
- 213 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- September 2019
Global
From €5183EUR$5,370USD£4,446GBP
- Report
- May 2019
- 171 Pages
Global
From €5183EUR$5,370USD£4,446GBP
- Report
- November 2023
- 160 Pages
Global
From €2895EUR$2,999USD£2,483GBP
Prevnar is a vaccine used to protect against pneumococcal disease, a type of bacterial infection that can cause serious illnesses such as pneumonia, meningitis, and sepsis. It is recommended for infants and young children, as well as adults over the age of 65. Prevnar is a conjugate vaccine, meaning it contains a combination of bacterial antigens that stimulate the body's immune system to produce antibodies. The vaccine is administered in a series of four doses, with the first dose given at two months of age.
The Prevnar market is highly competitive, with several major players offering their own versions of the vaccine. These include Pfizer, Merck, GlaxoSmithKline, Sanofi Pasteur, and AstraZeneca. Each company has its own unique formulation of the vaccine, which is designed to provide the best protection against pneumococcal disease. Show Less Read more